Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease
- 1 August 2005
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 79 (4) , 337-339
Abstract
Two human immunodeficiency virus‐infected patients who needed etoposide therapy to control exacerbations of Castleman disease received four infusions of rituximab. Clinical and virologic relapses with increased blood human herpesvirus‐8 DNA levels occurred in both patients 4 and 24 weeks later and were associated with a worsening of Kaposi sarcoma. Am. J. Hematol. 79:337–339, 2005.Keywords
This publication has 9 references indexed in Scilit:
- Multicentric Castleman's diseaseAIDS, 2004
- Rituximab therapy for HIV-associated Castleman diseaseBlood, 2003
- Prolonged remission of HIV-associated multicentric Castelmanʼs disease with an anti-CD20 monoclonal antibody as primary therapyAIDS, 2003
- Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximabBlood, 2002
- Long-term remission of Kaposi sarcoma–associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapyBlood, 2001
- Treatment of HIV-associated multicentric Castleman's disease with oral etoposideAmerican Journal of Hematology, 2001
- High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patientsBlood, 2000
- Multicentric Castlemanʼs disease in HIV infectionAIDS, 1996
- Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease [see comments]Blood, 1995